New drug combo targets breast cancer in the brain
NCT ID NCT01494662
First seen Jan 25, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study tested whether the oral drug neratinib, alone or with other medicines, can shrink or stabilize breast cancer that has spread to the brain in people with HER2-positive disease. About 140 participants received different treatment combinations. The main goal was to see how many patients had their brain tumors shrink significantly. This is a disease-control study, not a cure, because ongoing treatment is typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arnold Palmer Cancer Center-Greensburg
Greensburg, Pennsylvania, 15601, United States
-
Baylor College of Medicine Lester and Sue Smith Breast Center
Houston, Texas, 77030, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02215, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
MedStar Georgetown Univeristy Hospital
Washington D.C., District of Columbia, 20007, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
-
UPMC Cancer Centers - Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UPMC Ortenzio Cancer Center
Mechanicsburg, Pennsylvania, 17050, United States
-
UPMC Passavant Cranberry
Cranberry Township, Pennsylvania, 16066, United States
-
UPMC Pinnacle Harrisburg
Harrisburg, Pennsylvania, 17101, United States
-
University of California, San Francisco Medical Center
San Francisco, California, 94115, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.